We will likely add Lilly into the mix, by tomorrow night -- but see the updated totals at right, and the deets. . . as to Amgen:
. . .Issues related to drug pricing; Issues related to cardiovascular disease awareness and treatment; Issues related to FDA; Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters; Issues related to biosimilars reimbursement; Issues related to Supply Chain; Issues related to 340B; Issues related to pharmacy benefit managers; Issues related to biosimilars regulatory standards; Issues related to bone disease awareness and treatment; Issues related to Public law 117-1769 Inflation Reduction Act; Issues pertaining to the implementation of PL 97-414 "Orphan Drug Act," all provisions; HR 946 Optimizing Research Progress Hope and New Cures Act; HR 1492 Ensuring Pathways to Innovative Cures Act; HR 1672 Maintaining Investments in New Innovation Act; HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14); S 1954 Biosimilar Red Tape Elimination Act; HR 5526 Biosimilar Red Tape Elimination Act; HR 2214 DRUG Act; H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025; HR 5509 Safe Step act; HR 5256 340B Access Act; HR 4581 340B Patients Act; S2296 NDAA FY2026 National Defense Authorization Act, issued related to Biosecure Act. . . .
Issues related to drug pricing; Issues related to Public law 117-1769 Inflation Reduction Act; Issues related to cardiovascular disease awareness and treatment; Issues related to reimbursement for biologics/biosimilars; Issues related to PBM reform; Issues related to bone disease awareness and treatment; HR 946 Optimizing Research Progress Hope and New Cures Act; HR 1492 Ensuring Pathways to Innovative Cures Act; HR 1672 Maintaining Investments in New Innovation Act; HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14); H.R.1968 - Full-Year Continuing Appropriations and Extensions Act, 2025. . . .
Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act; Issues related to Puerto Rico; Issues related to OECD negotiations on the taxation of global income; HR 1 One Big Beautiful Bill Act (An Act to provide for reconciliation pursuant to title II of H. Con. Res. 14). . . .
Issues related to tariffs. . . .
Federal Trade Commission related issues, no specific bill; Issues related to the Patent Act, no specific bill; Issues related to March-In/Bayh Dole, WTO/TRIPS waiver, no specific bill; Issues related to patent thickets/product hopping; Issues related to obviousness / double patenting; Issues related to FDA/PTO coordination; Issues related to skinny labeling; S.1041 A bill to amend title 35, United States Code, to address the infringement of patents that claim biological products, and for other purposes; S.1040 -A bill to amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes; S.2296-- NDAA (FY 2026 National Defense Authorization Act-- BIOSECURE language); S 708/ HR 1574 -- Realizing Engineering, Science and Technology Opportunities by Restoring Exclusive Patent Rights Act of 2025 (RESTORE); S.1553/HR3160-- Promoting and Respecting Economically Viable American Innovation Act (PREVAIL); S. 1546/ HR 3152-- Patent Eligibility Restoration Act of 2025 (PERA). . . .
Now you know. . . "you have to break a few eggs, to make an. . . omelet." And, separately, all solved on the LaGuardia run, and music venue set-up is underway, for later tonight, at the House of Blues. Grin. Onward. . . .
नमस्ते
No comments:
Post a Comment